USA flag logo/image

An Official Website of the United States Government

Enhancing the Pharmacokinetic Profile of Protein-based Drugs

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
C122-101-0073
Solicitation Year:
2012
Solicitation Topic Code:
CBD12-101
Solicitation Number:
2012.2
Small Business Information
EXTEND BIOSCIENCES, INC.
48 Russell St. #3 CAMBRIDGE, MA 02140-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Enhancing the Pharmacokinetic Profile of Protein-based Drugs
Agency: DOD
Contract: W911NF-13-C-0033
Award Amount: $99,999.00
 

Abstract:

Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability when given subcutaneously. Extend Biosciences is developing proprietary carrier molecules that will allow proteins to access a transport pathway for efficient delivery to the vascular space and then maintain a sustained presence in circulation. This would be of particular importance in the development of longer-lasting versions of bioscavenger proteins that could then be delivered subcutaneously and become bioavailable within minutes of administration. In this project, one of Extend Biosciences"carrier molecules will be conjugated to two bioscavenger proteins of interest to the military as further proof-of-concept for the technology. The modified bioscavengers will be assayed in vitro to ensure that the carrier molecule does not disrupt functional activity. Following success in Phase I, the Phase II studies would test the modified bioscavengers for their improved half-life and bioavailability when delivered subcutaneously in an appropriate animal model, and test whether the modified protein induces toxicity or an immune response. This project will demonstrate the feasibility of improving the half-life and bioavailability of bioscavenger proteins that could be applied to numerous other protein-based drugs including those used in Chemical and Biological Defense treatments.

Principal Investigator:

Laura M. Hales
Chief Scientific Officer
(732) 599-8581
lhales@extendbio.com

Business Contact:

Tarik M. Soliman
Chief Executive Officer
(732) 599-8580
tsoliman@extendbio.com
Small Business Information at Submission:

Extend Biosciences Inc.
48 Russell St. #3 Cambridge, MA -

EIN/Tax ID: 272280039
DUNS: N/A
Number of Employees:
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No